Clinical applications and anticancer effects of antimicrobial peptides: from bench to bedside

A Jafari, A Babajani, R Sarrami Forooshani… - Frontiers in …, 2022 - frontiersin.org
Cancer is a multifaceted global health issue and one of the leading causes of death
worldwide. In recent years, medical science has achieved great advances in the diagnosis …

Cellular and molecular evidence of multiple sclerosis diagnosis and treatment challenges

Z Khan, GD Gupta, S Mehan - Journal of clinical medicine, 2023 - mdpi.com
Multiple sclerosis (MS) is a chronic autoimmune disease that impacts the central nervous
system and can result in disability. Although the prevalence of MS has increased in India …

The cross-talks among bone morphogenetic protein (BMP) signaling and other prominent pathways involved in neural differentiation

A Manzari-Tavakoli, A Babajani, MH Farjoo… - Frontiers in Molecular …, 2022 - frontiersin.org
The bone morphogenetic proteins (BMPs) are a group of potent morphogens which are
critical for the patterning, development, and function of the central nervous system. The …

Emerging biomarkers for non-invasive diagnosis and treatment of cancer: a systematic review

S Zakari, NK Niels, GV Olagunju, PC Nnaji… - Frontiers in …, 2024 - pmc.ncbi.nlm.nih.gov
Cancer remains a global health challenge, necessitating continuous advancements in
diagnostic and treatment strategies. This review focuses on the utility of non-invasive …

Analytical validation of a multi‐protein, serum‐based assay for disease activity assessments in multiple sclerosis

F Qureshi, W Hu, L Loh, H Patel… - PROTEOMICS …, 2023 - Wiley Online Library
Purpose To characterize and analytically validate the MSDA Test, a multi‐protein, serum‐
based biomarker assay developed using Olink® PEA methodology. Experimental design …

[HTML][HTML] Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis

T Chitnis, J Foley, C Ionete, NK El Ayoubi, S Saxena… - Clinical …, 2023 - Elsevier
An 18-protein multiple sclerosis (MS) disease activity (DA) test was validated based on
associations between algorithm scores and clinical/radiographic assessments (N= 614 …

A scoping review on body fluid biomarkers for prognosis and disease activity in patients with multiple sclerosis

N Barizzone, M Leone, A Pizzino, I Kockum… - Journal of Personalized …, 2022 - mdpi.com
Multiple sclerosis (MS) is a complex demyelinating disease of the central nervous system,
presenting with different clinical forms, including clinically isolated syndrome (CIS), which is …

Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis

L Lorefice, M Pitzalis, F Murgia, G Fenu, L Atzori… - Frontiers in …, 2023 - frontiersin.org
From the perspective of precision medicine, the challenge for the future is to improve the
accuracy of diagnosis, prognosis, and prediction of therapeutic responses through the …

[HTML][HTML] Unveiling diagnostic and therapeutic strategies for cervical cancer: biomarker discovery through proteomics approaches and exploring the role of cervical …

A Jafari, M Farahani, M Abdollahpour-Alitappeh… - Frontiers in …, 2024 - frontiersin.org
Cervical cancer (CC) is a major global health problem and leading cause of cancer deaths
among women worldwide. Early detection through screening programs has reduced …

Untargeted metabolomic profiling of cuprizone‐induced demyelination in mouse corpus callosum by UPLC‐orbitrap/MS reveals potential metabolic biomarkers of …

Z Zhao, T Li, X Dong, X Wang, Z Zhang… - Oxidative medicine …, 2021 - Wiley Online Library
Multiple sclerosis (MS) is a neurodegenerative disorder characterized by periodic neuronal
demyelination, which leads to a range of symptoms and eventually to disability. The goal of …